Reinventing mental healthcare with precision neuromedicines.
Advancing a Precision Medicine Approach to Mental Health Disorders, starting with PTSD.
Current mental healthcare tools are inadequate, leaving tens of millions of people suffering. PTSD healthcare is no exception, characterized by failures to understand and address its root cause.
Our approach is different. With our deep understanding of receptor biology, neuroscience, and translational medicine, we have developed a novel drug discovery platform, which we are using to develop precision medications to treat CNS diseases at the source—the most logical target.
Latest News
-
Neurovation Labs Awarded 3rd U.S. Patent, Covering Brain Biomarker Detection
April 15, 2025
-
Caring for a Veteran with PTSD: Essential Tools for Caregivers
July 2024
-
Dr. Perusini featured in Project W "2023 Impact Report"
January 2024
Events
-
CEO Jennifer Perusini panelist on PTSD and Depression: What Caregivers Need to Know
June 3, 2025
CEO Jennifer Perusini will be a panelist in this educational session designed for caregivers, family members, and friends from Families for Depression Awareness.
-
CEO Jennifer Perusini to present at Barnard College's 5th Annual Startup Summit
June 6, 2025
CEO Jennifer Perusini to present at 4th Annual Startup Summit, hosted by Barnard College's Athena Center for Leadership and Barnard Entrepreneurs Network.
-
CEO Jennifer Perusini presenting at 2025 Pavlovian Society Annual Meeting
August 6, 2025
CEO Jennifer Perusini was selected as a speaker at the 2025 Pavlovian Society Annual Meeting to discuss Neurovation Labs' research and developments.